Nov 19, 2024 07:00AM
Apr 17, 2023 02:32PM
Apr 17, 2023 02:30PM
Sep 21, 2020 07:00AM
Aug 6, 2020 04:05PM
Jul 1, 2020 07:00AM
Jun 22, 2020 09:04AM BeiGene (BGNE) and SpringWorks (SWTX) Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clini
Jun 22, 2020 09:00AM
Jun 18, 2020 07:36AM
Jun 18, 2020 07:30AM
Jun 12, 2020 02:30AM
Jun 3, 2020 07:16AM
Jun 3, 2020 07:15AM
May 29, 2020 08:00AM BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (AS
May 21, 2020 07:07AM
May 21, 2020 07:00AM
May 11, 2020 04:05PM
Mar 2, 2020 04:05PM
Feb 27, 2020 07:14AM
Dec 30, 2019 05:48AM
Dec 27, 2019 10:30PM China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies
Dec 22, 2019 06:00PM
Dec 16, 2019 07:02AM
Dec 16, 2019 07:00AM
Dec 9, 2019 06:18AM
Dec 8, 2019 04:45PM
Nov 14, 2019 04:30PM
Nov 14, 2019 04:20PM U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy
Nov 12, 2019 04:05PM
Sep 23, 2019 06:21AM
Aug 21, 2019 04:30PM
Jun 20, 2019 11:08AM
Jun 20, 2019 11:05AM
Jun 20, 2019 07:48AM
Jun 20, 2019 07:45AM BeiGene Presents Pivotal Phase 2 Clinical Results of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 15th International Conference o
Jun 19, 2019 11:22AM
Jun 19, 2019 11:21AM
Jun 14, 2019 02:30AM
Jun 12, 2019 04:00AM
Jun 3, 2019 05:43AM
May 30, 2019 07:00PM
Feb 27, 2019 04:15PM BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 19, 2019 04:30PM
Jan 14, 2019 04:15PM
Dec 1, 2018 03:45PM
Nov 7, 2018 07:00AM
Nov 7, 2018 07:00AM
Oct 24, 2018 07:17AM
Oct 24, 2018 07:00AM BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymp
Oct 11, 2018 06:00AM

332,148 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All